Intercept Pharmaceuticals' shares have been halted ahead of the FDA AdCom meeting. The outcome of the meeting, which will discuss the company's liver disease drug, Ocaliva, may have a significant impact on the stock price. A positive outcome could lead to an increase in the stock price, while a negative outcome could result in a decrease. As the news is directly related to the company and its product, the relevance is high. The importance is also high, as the outcome of the meeting could have a significant impact on the company's future. The confidence in the analysis is 90% as the news is directly related to the company and its product.